Can an oncolytic virus therapy challenge the longstanding standard of care in bladder cancer? CG Oncology has $120M to find out

CG Oncology is cashing in on its interim data update.

Tuesday morning, the Irvine, CA-based biotech announced that it raised $120 million — eclipsing the combined $87 million it’s brought in since its inception 12 years ago. The raise comes after CG posted updated data at SITC for its oncolytic...

Click to view original post